Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the overcast skies hovering above the Pharmalot campus. Our official mascot is curled up nearby and snoozing happily. And the coffee kettle is whistling once again in preparation for another delicious cup of stimulation. In other words, the proverbial coffee cup is half full. Better than half empty, yes? On that note, it is time, once again, to get cracking. Here are a few tidbits to help you on your journey. Hope today goes well, and do keep in touch. …

Shenzhen Kangtai Biological Products will produce a Covid-19 vaccine in mainland China that is being developed by AstraZeneca (AZN), its first deal to supply one of the world’s most populous countries, Reuters notes. The deal underscores a global race to deliver an effective vaccine, given that Chinese ventures are leading at least eight of the 26 global vaccine development projects currently testing in humans. Under the deal, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!